甘精胰岛素U300联合口服降糖药治疗2型糖尿病的临床效果观察  

Clinical Effect Observation of Insulin Glargine U300 Combined With Oral Hypoglycemic Medicine on Type 2 Diabetes

作　　者：吴晓[1] 陈华生[2] WU Xiao;CHEN Huasheng(Department of Endocrinology,Wuchuan People’s Hospital,Guangdong Province,Wuchuan Guangdong 524500,China;Department of Clinical Pharmacy,Wuchuan People’s Hospital,Guangdong Province,Wuchuan Guangdong 524500,China)

机构地区：[1]广东省吴川市人民医院内分泌科,广东吴川524500 [2]广东省吴川市人民医院临床药学室,广东吴川524500

出　　处：《中国卫生标准管理》2024年第3期108-111,共4页China Health Standard Management

摘　　要：目的探讨甘精胰岛素U300联合口服降糖药治疗2型糖尿病的临床效果。方法选择2021年10月—2023年1月广东省吴川市人民医院收治的79例2型糖尿病患者,随机分为非甘精组(39例)和U300组(40例)。非甘精组口服降糖药物治疗,在此之上,U300组增加甘精胰岛素U300治疗,持续治疗3个月,对比2组血糖及相关指标变化,并监测患者胰岛素功能相关指标改善情况,评估低血糖反应等不良反应情况。结果治疗后,U300组血糖指标、血糖波动指标均显著低于非甘精组,差异有统计学意义(P<0.05)。U300组治疗后胰岛素功能指标均显著优于非甘精组,空腹及餐后2 h C肽均显著高于非甘精组,差异有统计学意义(P<0.05)。U300组低血糖反应发生率(2.50%,1/40)和不良反应总发生率(20.00%,8/40)与非甘精组(2.56,1/39;17.95%,7/39)比较,差异无统计学意义(P>0.05)。结论增加甘精胰岛素U300治疗,可更好地提升患者血糖管理效果,并可改善胰岛功能,有利于稳定控制血糖,有助于提高患者病情控制效果,应用效果安全可靠。Objective To explore the clinical effect of insulin glargine U300 combined with oral hypoglycemic medicine in the treatment of type 2 diabetes.Methods A total of 79 patients with type 2 diabetes who were admitted to Wuchuan People’s Hospital,Guangdong Province from October 2021 to January 2023 were randomly divided into non-glycyrrhizin group(39 cases)and U300 group(40 cases).The non-glycine group was received oral hypoglycemic drug treatment.On top of this,the U300 group was received insulin glargine U300 treatment for 3 months.The changes in blood glucose and related indicators were compared between the two groups,and the improvement of insulin function related indicators was monitored to evaluate adverse reactions such as hypoglycemic reactions.Results After treatment,the blood glucose indicators and blood glucose fluctuation indicators in the U300 group were significantly lower than those in the non-glycine group,the differences were statistically significant(P<0.05).After treatment,the insulin function indicators in the U300 group were significantly better than those in the non-glargine group,and the fasting and 2-hour postprandial C-peptide levels were significantly higher than those in the non-glargine group,the differences were statistically significant(P<0.05).The incidence of hypoglycemic reactions(2.50%,1/40)and total incidence of adverse reactions(20.00%,8/40)in the U300 group were not statistically significant compared to the non-glyceride group(2.56%,1/39;17.95%,7/39)(P>0.05).Conclusion The increase of insulin glargine U300 treatment can better improve the blood glucose management effect of patients,and improve islet function,which is conducive to the stable control of blood glucose,and helps to improve the control effect of patients'condition.The application effect is safe and reliable.

关 键 词：甘精胰岛素U300 口服降糖药 联合治疗 2型糖尿病 血糖 胰岛功能 低血糖反应 

分 类 号：R587[医药卫生—内分泌]